| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
8.35(B) |
| Last
Volume: |
3,979,543 |
Avg
Vol: |
1,940,342 |
| 52
Week Range: |
$50.38 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
33,920 |
108,398 |
166,494 |
290,334 |
| Total Sell Value |
$2,062,221 |
$6,570,910 |
$11,277,891 |
$18,676,003 |
| Total People Sold |
10 |
10 |
11 |
11 |
| Total Sell Transactions |
20 |
52 |
61 |
100 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Conroy Kevin T |
President and CEO |
• • – |
2020-08-03 |
4 |
AS |
$93.79 |
$2,363,560 |
D/D |
(25,198) |
968,266 |
|
37% |
|
| Napier Katherine S |
Director |
– • – |
2020-07-31 |
4 |
AS |
$94.00 |
$1,976,726 |
D/D |
(21,029) |
41,907 |
|
37% |
|
| Napier Katherine S |
Director |
– • – |
2020-07-31 |
4 |
OE |
$8.52 |
$179,167 |
D/D |
21,029 |
62,936 |
|
- |
|
| Levangie Daniel J |
Director |
– • – |
2020-07-31 |
4 |
AS |
$94.00 |
$927,310 |
D/D |
(9,865) |
15,016 |
|
37% |
|
| Levangie Daniel J |
Director |
– • – |
2020-07-31 |
4 |
OE |
$8.52 |
$91,699 |
D/D |
9,865 |
24,881 |
|
- |
|
| Carey Thomas D. |
Director |
– • – |
2020-07-31 |
4 |
AS |
$94.00 |
$2,878,280 |
D/D |
(30,620) |
21,872 |
|
37% |
|
| Carey Thomas D. |
Director |
– • – |
2020-07-31 |
4 |
OE |
$9.24 |
$144,329 |
D/D |
15,620 |
52,492 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2020-07-31 |
4 |
AS |
$91.18 |
$3,518,771 |
D/D |
(37,500) |
38,361 |
|
37% |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2020-07-31 |
4 |
OE |
$21.68 |
$143,912 |
D/D |
6,638 |
75,861 |
|
- |
|
| Doyle James Edward |
Director |
– • – |
2020-07-31 |
4 |
AS |
$94.00 |
$238,666 |
D/D |
(2,539) |
32,459 |
|
37% |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2020-07-29 |
4 |
S |
$95.58 |
$835,943 |
D/D |
(8,746) |
69,223 |
|
-38% |
|
| Napier Katherine S |
Director |
– • – |
2020-07-28 |
4 |
AS |
$96.13 |
$111,895 |
D/D |
(1,164) |
41,907 |
|
41% |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2020-07-28 |
4 |
OE |
$94.81 |
$1,777,688 |
D/D |
18,750 |
77,969 |
|
- |
|
| Wyzga Michael S |
Director |
– • – |
2020-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,558 |
11,471 |
|
- |
|
| Lewis-Hall Freda C |
Director |
– • – |
2020-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
3,408 |
8,472 |
|
- |
|
| Doyle James Edward |
Director |
– • – |
2020-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,558 |
34,998 |
|
- |
|
| Sebelius Kathleen |
Director |
– • – |
2020-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,558 |
10,758 |
|
- |
|
| Petrovic Shacey |
Director |
– • – |
2020-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,558 |
6,346 |
|
- |
|
| Napier Katherine S |
Director |
– • – |
2020-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,558 |
43,071 |
|
- |
|
| Levangie Daniel J |
Director |
– • – |
2020-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,558 |
15,016 |
|
- |
|
| Slavitt Andrew M |
Director |
– • – |
2020-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,558 |
9,445 |
|
- |
|
| Jacquet Pierre |
Director |
– • – |
2020-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,752 |
8,734 |
|
- |
|
| Casdin Eli |
Director |
– • – |
2020-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,558 |
8,820 |
|
- |
|
| Carey Thomas D. |
Director |
– • – |
2020-07-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,691 |
36,872 |
|
- |
|
| Petrovic Shacey |
Director |
– • – |
2020-07-22 |
4 |
A |
$0.00 |
$0 |
D/D |
3,788 |
3,788 |
|
- |
|
777 Records found
|
|
Page 15 of 32 |
|
|
2.82 (5.66%) 
